The role of 'extra' DNA in cancer evolution and therapy resistance

April 23, 2018 by Sarah Laskowski, Henry Ford Health System
Credit: Henry Ford Health System

Glioblastoma (GBM) is the most common and aggressive form of brain cancer. Response to standard-of-care treatment is poor, with a two-year survival rate of only 15 percent. Research is beginning to provide a better understanding of the processes underlying cell-to-cell differences within GBM tumors - a crucial finding because these differences contribute to therapy resistance.

The ultimate goal is to identify what pathways can be targeted to block glioma progression.

To this end, a multi-institutional team led by Professor Roel Verhaak, Ph.D., of The Jackson Laboratory (JAX) and Ana C. deCarvalho, Ph.D., Assistant Professor from Henry Ford Health System's Hermelin Brain Tumor Center in Detroit, MI, tracked genomic alterations detected in patient samples during tumor cell evolution in culture, in patient-derived xenograft (PDX) mouse models from the cultures, as well as before and after treatment in patients. In a recent paper in Nature Genetics, the team reports that tumor progression was often driven by -promoting genes, known as oncogenes, on extrachromosomal pieces of DNA.

Detailed analyses of the from patient to culture to mouse revealed that, for the most part, the cells retained the same genomic lesions. This is good news overall, as it indicates that PDX mice can provide a relatively accurate and effective experimental platform for GBM. The primary caveat was the finding that in a few cases, the numbers of copies differed between tumors and the cultures and PDX mouse samples derived from them. If an oncogene is increased, or amplified, that can both cause and maintain cancer, so differences in gene amplification can be very important.

But why did the levels of oncogene amplification change? What the researchers found was that the differences were caused by oncogenes that weren't part of chromosome sequences as usual. Instead, they were on separate circular pieces of DNA, known as extrachromosomal (ec) DNA. These pieces of DNA are not found in normal cells, and cause major increases in the expression of oncogenes. More detailed investigation showed that many instances of oncogene amplification found in the glioma tumors involved ecDNA elements.

"The selective advantage conferred to tumor cells by the regulation of oncogene copy number in ecDNA has not been sufficiently addressed in interpreting results in the laboratory or in clinical trials. Using the GBM patient-derived models carrying ecDNA amplification of the most frequent oncogenes, we are developing and testing novel combination therapies specific for each unique tumor," says deCarvalho.

ecDNA elements were first observed directly under microscopes in cancer cells more than 50 years ago, but it remains unknown how they arise in the first place. Technological limitations have impeded studies of ecDNA in detail, despite a recent publication in Nature suggesting their presence in nearly half of cancers. In fact, their role in disease has not been extensively studied, but it's an important topic. Unlike chromosomal DNA, ecDNA is inherited inconsistently as a tumor grows. That is, when a cancer cell divides, the DNA on the chromosomes almost always gets accurately duplicated and remains the same in the . But ecDNA inheritance appears to be far more random. Sometimes both daughter cells inherit ecDNA, but sometimes all or most of it will end up in one cell and not the other.

"The process quickly creates important differences between cells within the same , and it helps accelerate the evolution of the cancer," says Verhaak. "It provides the cells with more ways to evade stress. Therefore, there's a better chance that at least some of the will survive severe stress, such as stresses caused by a chemotherapy or radiation."

One reason ecDNA has been relatively ignored is that it's hard to detect using standard sequencing methods, which don't accurately detect and separate it from chromosomal DNA. But it's now attracting more attention, and the work moving forward will likely help explain why cancers such as GBM are difficult to treat and evolve therapy resistance so rapidly.

"We think targeting ecDNA has huge potential for the development of new cancer treatments" says Verhaak. "We're now working to develop sequencing-based protocols to identify ecDNA more efficiently. The bigger goal is to learn how and why ecDNA elements form. If we can block those mechanisms, we'll have a way to prevent the evolution, and perhaps even the formation, of many cancers."

Explore further: New research will shift how cancer diversity and resistance are understood and studied

More information: Ana C. deCarvalho et al, Discordant inheritance of chromosomal and extrachromosomal DNA elements contributes to dynamic disease evolution in glioblastoma, Nature Genetics (2018). DOI: 10.1038/s41588-018-0105-0

Related Stories

New research will shift how cancer diversity and resistance are understood and studied

February 8, 2017
A paradigm-changing Ludwig Cancer Research study reveals that short fragments of circular DNA that encode cancer genes are far more common in cancer cells than previously believed and probably play a central role in generating ...

New liquid biopsy-based cancer model reveals data on deadly lung cancer

April 15, 2018
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University ...

Scientists target glioma cancer stem cells, which could improve patient survival

February 5, 2018
Glioblastoma multiforme is the most common and aggressive primary brain tumor and has one of the worst survival rates of all cancers. Despite surgery, radiation and chemotherapy, these tumors virtually always become resistant ...

Gene duplication explains tumor aggressiveness

January 31, 2018
Pancreatic cancer is a form of cancer associated with the highest mortality rates in the world. Genetic changes that could explain its aggressiveness and early metastasis are elusive. A team at Technical University of Munich ...

Cancer comes back all jacked up on stem cells

March 19, 2018
After a biopsy or surgery, doctors often get a molecular snapshot of a patient's tumor. This snapshot is important - knowing the genetics that cause a cancer can help match a patient with a genetically-targeted treatment. ...

Glioblastoma 'ecosystem' redefined for more effective immunotherapy trials

July 10, 2017
A research team has revealed the intrinsic gene expression patterns of glioblastoma (GBM) tumors, insights that could drive more effective treatments for GBM, the most common and deadly malignant primary brain tumors in adults.

Recommended for you

Study finds gut microbiome can control antitumor immune function in liver

May 24, 2018
Scientists have found a connection between bacteria in the gut and antitumor immune responses in the liver. Their study, published May 25 in Science, was led by researchers in the Center for Cancer Research (CCR) at the National ...

New findings on autism-related disorder

May 24, 2018
In a study published today in Nature, Marc Bühler and his group at the Friedrich Miescher Institute for Biomedical Research (FMI) have taken a major step forward in elucidating the mechanisms underlying a disorder known ...

Low-fat diet tied to better breast cancer survival

May 24, 2018
(HealthDay)—Breast cancer patients who adopted a low-fat diet were more likely to survive for at least a decade after diagnosis, compared to patients who ate fattier fare, new research shows.

Genome study presents new way to track historical demographics of US populations

May 24, 2018
Sharon Browning of the University of Washington and colleagues developed a method to estimate historical effective population size, which is the number of individuals who pass on their genes to the next generation, to reveal ...

A cascade of immune processes offers insights to triple-negative breast cancer

May 24, 2018
Cancer is crafty. To survive and thrive, tumors find a way of thwarting our body's natural systems.

By forming clots in tumors, immune cell aids lung cancer's spread

May 24, 2018
University of North Carolina Lineberger Comprehensive Cancer Center researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation ...

1 comment

Adjust slider to filter visible comments by rank

Display comments: newest first

Parsec
not rated yet Apr 23, 2018
Please indulge me for a moment of wild speculation. If cells were able to produce these small ecDNA's in non cancerous cells under stress, then their presence in germline cells would allow species to have enhanced evolution in response to stressful conditions. The cost of course would be a huge spike in cancers, but if it also resulted in germline mutations better able to handle the stress it would be worth it for the species as a hole.

I am basically postulating that a species could increase its background mutation rate when placed under stress. That would not only be a fascinating development, but would place static molecular clocks under considerable theoretical strain.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.